Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067621 · ClinicalTrials.gov registry record · Phase 2
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
A Phase 2 study of Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05067621: Recruiting Phase 2 study of Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease, sponsored by Yale University.
NCT05067621 is a Phase 2 study of Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by Yale University. The registered enrollment target is 60 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05067621, a Phase 2 study of Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
Primary Outcome
The oDI value is the product of total responsivity index and insulin sensitivity. The change in oDI from baseline to 6M on treatment is calculated as the difference between 6M oDI value and baseline oDI value. The oDI measures the ability of beta-cell to respond to a glucose stimulus.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide Pen Injector
Study Locations (1)
Connecticut
- Pediatric Diabetes Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-07-17 |
| Est. Completion | 2027-01 |
| Phase | Phase 2 |
What NCT05067621 shows while recruiting
NCT05067621 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05067621 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05067621 about?
NCT05067621 is a clinical study titled "Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease". The purpose of this study is to understand the role of GLP-1 in the pathogenesis of T2D in youth and explore their potential salutary effects and ability to delay the progressive loss of ß-cell function and reduce hepatic steatosis in youth with prediabetes/new onset T2D and NAFLD.
What is the current status of trial NCT05067621?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-07-17. Estimated completion is 2027-01.
What conditions does trial NCT05067621 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Non-alcoholic Fatty Liver Disease, Obesity, Childhood, Impaired Glucose Tolerance.
What interventions are being tested in trial NCT05067621?
The interventions under investigation include: Placebo (DRUG), Semaglutide Pen Injector (DRUG).
Who is sponsoring clinical trial NCT05067621?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05067621 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05067621's enrollment target sits among peer trials
60 72nd of 130 higher than 56 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes
RECRUITING · Phase 2
-
Regulation of Endogenous Glucose Production by Central KATP Channels
RECRUITING · Phase 2
-
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
COMPLETED · Phase 2
-
The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes
COMPLETED · Phase 2
-
Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI